Table 1 Patient characteristics.
Pt | Age | Sex | Disease and stage at diagnosis | Lines prior to HCT | BsAb | No. of BsAb doses | Washout between BsAb and HCT (days) | Disease status at HCT | HCT-CI | DRI | Type of HCT | Conditioning regimen | GVHD prophylaxis | Complications | Status | Time from HCT to death or last FU, days | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 59 | F | tDLBCL, IIA | RT; R-CHOP; Bend; R-ESHAP | Glofitamab 220 mcg at day +1 and +8 (plus SD of O 1.000 mg at day -7) | 10 | 71 | PR | 5 | Int | Haplo | TBF MAC | PT-Cy/Tac/MMF | Grade 1 acute GVHD (skin) | Dead | 623 | POD |
2 | 57 | M | tDLBCL, IVA | R-CHOP; R-ESHAP + ASCT | Glofitamab 1.800 mcg + 1.200 mg Atezolizumab at day +1 | 5 | 34 | CR | 2 | Low | 10/10 MRD (son) | TBF RIC | PT-Cy/Tac/MMFa | Moderate chronic GVHD (GI tract + lungs) | Dead | 257 | GVHD (in the setting of an infection) |
3 | 52 | F | DLBCL, IVB | R-CHOP; R-GDP | Glofitamab 1.800 mcg + 1.200 mg Atezolizumab at day +1 | 8 | 50 | CR | 3 | Int | Haplo | TBF RIC | PT-Cy/CsA/MMF | Candidemia at day +118 | Alive | 1110 | - |
4 | 64 | M | MCL, IVB | R-hyperCVAD + ASCT; Ibrutinib; R-GemOx; R-ICE | Glofitamab 10 mg + Polatuzumab 1.8 mg/Kg at day +1 of each cycle (plus SD of O 1.000 mg) | 4 | 24 | CR | 0 | Int | Haplo | TBF RIC | PT-Cy/Tac/MMF | Grade 2 acute GVHD (GI tract) Chronic GVHD | Dead | 258 | GVHD (in the setting of an infection) |
5 | 55 | M | DLBCL, IIIA | R-CHOP; AxiCel; R-GDP | Glofitamab 10 mg + Polatuzumab 1.8 mg/Kg at day +1 of each cycle (plus SD of O 1.000 mg) | 20 | 51 | PR | 0 | Int | Haplo | TBF MAC | PT-Cy/Tac/MMF | Alive | 705 | - | |
6 | 67 | M | DLBCL, IVA | R-CHOP; R-GDP; R-ICE; TisaCel; Cy-PDN; RT | Epcoritamab (160 mcg D1, 800 mcg D8, 60.000 mcg at D15 and beyond) | 10 | 23 | CR | 5 | Int | Haplo | TBF RIC | PT-Cy/Tac/MMF | Primary poor graft function. Suspicion of venooclusive disease. | Dead | 67 | Infection (septic shock) |
7 | 64 | F | FL, IVA | R-CHOP; R-GDP | Epcoritamab (160 mcg D1, 800 mcg D8, 48.000 mcg at D15 and beyond) | 13 | 27 | CR | 0 | Low | 10/10 MUD | TBF RIC | PT-Cy/Tac/MMF | Candidemia at day +25 | Dead | 28 | Infection (septic shock) |
8 | 48 | M | FL, IVA | R-CHOP; R-ESHAP; Bend + ASCT | Epcoritamab (160 mcg D1, 800 mcg D8, 48.000 mcg at D15 and beyond) | 11 | 50 | CR | 0 | Low | 9/10 MUD | TBF RIC | PT-Cy/Tac/MMF | Central nervous System toxoplasmosis | Dead | 28 | Death before engraftment at day +27 due to disseminated toxoplasmosis. |
